Results 81 to 90 of about 18,118,892 (286)

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Therapies for Advanced Parkinson’s Disease in Sweden: A Cost-Effectiveness Analysis Using Real-World Data

Neurology and Therapy
Introduction The Swedish Parkinson’s Disease (PD) Registry provides rich data on cost and quality of life for patients receiving device-aided therapies (DATs) for Parkinson’s disease in Sweden.
Dag Nyholm, Simon Eggington, Astrid Holm
doaj   +1 more source

Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review

Expert Review of Vaccines, 2023
Introduction Studies on economic evaluations of the 13-valent pneumococcal conjugate vaccine (PCV13) have been increasing over the last decade. No systematic reviews have synthesized the evidence of economic evaluations of the PCV13.
Yuanze Du, Yi Wang, Ting Zhang, Juanjuan Li, Hewei Song, Yuanyuan Wang, Yifei Xu, Jingwen Cui, Ming Yang, Zengwu Wang, Xiuyun Wu, Chunping Wang   +11 more
doaj   +1 more source

Summarized results of willingness to pay per quality-adjusted life year in 64 studies.

Summarized results of willingness to pay per quality-adjusted life year in 64 studies.
Klas Göran Sahlen (17935584), Lars Lindholm (21685), Anh Nu Vu (17935581), Minh Van Hoang (6842081), Cuc Thi Thu Nguyen (14059662), Sun Sun (15469762)   +5 more
core   +1 more source

Summary of disability-adjusted life year calculation methods for brucellosis.

, 2022
Summary of disability-adjusted life year calculation methods for brucellosis.
David M. Pigott (8067494), Ben Huntington (14253576), Brecht Devleesschauwer (505283), Narmada Venkateswaran (14253573), Grace T. Patterson (12174272), Mieghan Bruce (4924051), Paul Torgerson (505285), Carlotta Di Bari (13007651), Christina Fastl (9473503), Jonathan Rushton (503844)   +9 more
core   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Cost effectiveness of bevacizumab plus carboplatin paclitaxel versus carboplatin paclitaxel as front line for advanced ovarian cancer in Thailand

Scientific Reports
Bevacizumab (BEV) combined with standard chemotherapy with carboplatin and paclitaxel (CP) as the front-line treatment for newly diagnosed advanced-stage epithelial ovarian cancer (EOC) is a promising treatment option.
Kanyarat Katanyoo, Usa Chaikledkaew, Nutthaporn Chandeying   +2 more
doaj   +1 more source

Comparison of the Quality of Life between Patients with Non-Small-Cell Lung Cancer and Healthy Controls

, 2012
We explored covariates of the quality of life (QOL) in non- small-cell lung cancer (NSCLC) patients and made a comparison with healthy controls. We assessed the QOL of 220 consecutive NSCLC patients at a university hospital. The QOL data were measured by
李俊賢;張郁瑩;李元麒;楊志新;劉紹興;劉邦祥;王榮德, LEE, LUKAS JYUHN-HSIARN;CHANG, YU-YIN;LEE, YUNG-CHIE;YANG, CHIH-HSIN;LIOU, SAOU-HSING;LIU, PANG-HSIANG;WANG, JUNG-DER   +1 more
core   +1 more source

Health-adjusted life expectancy of the British population [PDF]

, 2008
In this article, changes in the quality of health-adjusted life expectancy of the British population between 1991 and 1998 are analysed. It is found that at all given age levels, life expectancy increased during this period.
Groot, W., Groot, Wim, van den Brink, H.M., Maassen van den Brink, Henriette, Maassen van den Brink, H., Groot, W.N.J., H. M. van den Brink, W. Groot   +7 more
core   +1 more source